Insmed (NASDAQ:INSM)‘s stock had its “positive” rating reaffirmed by equities research analysts at Robert W. Baird in a report released on Thursday, The Fly reports. They presently have a $42.00 price target on the biopharmaceutical company’s stock, up from their prior price target of $32.00. Robert W. Baird’s price target indicates a potential upside of 27.31% from the stock’s current price.

Other research analysts have also recently issued reports about the company. HC Wainwright reaffirmed a “buy” rating and issued a $35.00 price target on shares of Insmed in a report on Monday, November 6th. Cowen reaffirmed a “buy” rating and issued a $54.00 price target on shares of Insmed in a report on Friday, November 3rd. Stifel Nicolaus reaffirmed a “buy” rating and issued a $43.00 price target (up from $27.00) on shares of Insmed in a report on Wednesday, September 6th. BidaskClub raised Insmed from a “sell” rating to a “hold” rating in a report on Friday, December 22nd. Finally, ValuEngine raised Insmed from a “sell” rating to a “hold” rating in a report on Wednesday, September 6th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and six have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $35.75.

Insmed (NASDAQ INSM) opened at $32.99 on Thursday. The stock has a market capitalization of $2,486.14, a price-to-earnings ratio of -10.61 and a beta of 1.18. Insmed has a twelve month low of $11.49 and a twelve month high of $33.54. The company has a debt-to-equity ratio of 0.13, a quick ratio of 15.21 and a current ratio of 15.21.

In other news, Director Donald J. Hayden, Jr. sold 15,000 shares of the business’s stock in a transaction dated Tuesday, November 14th. The stock was sold at an average price of $32.50, for a total transaction of $487,500.00. Following the completion of the transaction, the director now directly owns 71,131 shares in the company, valued at approximately $2,311,757.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 4.03% of the stock is owned by company insiders.

Several institutional investors have recently bought and sold shares of INSM. SG Americas Securities LLC bought a new position in shares of Insmed during the 2nd quarter valued at about $129,000. BNP Paribas Arbitrage SA lifted its holdings in shares of Insmed by 666.7% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 7,498 shares of the biopharmaceutical company’s stock valued at $129,000 after purchasing an additional 6,520 shares in the last quarter. Trexquant Investment LP bought a new position in shares of Insmed during the 4th quarter valued at about $140,000. Legal & General Group Plc lifted its holdings in shares of Insmed by 7.2% during the 1st quarter. Legal & General Group Plc now owns 14,289 shares of the biopharmaceutical company’s stock valued at $182,000 after purchasing an additional 959 shares in the last quarter. Finally, UBS Asset Management Americas Inc. bought a new position in shares of Insmed during the 2nd quarter valued at about $187,000. Institutional investors own 95.28% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was originally reported by American Banking News and is owned by of American Banking News. If you are reading this report on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark legislation. The correct version of this report can be accessed at https://www.americanbankingnews.com/2018/01/04/insmeds-insm-positive-rating-reaffirmed-at-robert-w-baird.html.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company. The Company operates through development and commercialization of therapies for patients with rare diseases segment. Its lead product candidate is ARIKAYCE, or liposomal amikacin for inhalation (LAI), which is in late-stage development for adult patients with treatment refractory nontuberculous mycobacteria (NTM) lung disease caused by Mycobacterium avium complex (MAC).

The Fly

Analyst Recommendations for Insmed (NASDAQ:INSM)

Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.